Clinical Trial Update: Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type [Phase 2]

View source ↗

Summary

Phase 2 trial of IPGDP regimen in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type is in an unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma Nasal Type

Drugs mentioned

• IPGDP regimen

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type | Phase 2 | Status: UNKNOWN